In last trading session, Dianthus Therapeutics Inc (NASDAQ:DNTH) saw 0.39 million shares changing hands with its beta currently measuring 1.73. Company’s recent per share price level of $23.80 trading at $0.76 or 3.30% at ring of the bell on the day assigns it a market valuation of $704.40M. That closing price of DNTH’s stock is at a discount of -41.89% from its 52-week high price of $33.77 and is indicating a premium of 69.92% from its 52-week low price of $7.16. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.17 million shares which gives us an average trading volume of 258.45K if we extend that period to 3-months.
For Dianthus Therapeutics Inc (DNTH), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.17. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.76 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
Upright in the green during last session for gaining 3.30%, in the last five days DNTH remained trading in the red while hitting it’s week-highest on Monday, 12/16/24 when the stock touched $23.80 price level, adding 3.45% to its value on the day. Dianthus Therapeutics Inc’s shares saw a change of 128.85% in year-to-date performance and have moved -0.04% in past 5-day. Dianthus Therapeutics Inc (NASDAQ:DNTH) showed a performance of 14.59% in past 30-days. Number of shares sold short was 5.61 million shares which calculate 18.78 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 52 to the stock, which implies a rise of 54.23% to its current value. Analysts have been projecting 52 as a low price target for the stock while placing it at a high target of 52. It follows that stock’s current price would drop -118.49% in reaching the projected high whereas dropping to the targeted low would mean a loss of -118.49% for stock’s current value.
Dianthus Therapeutics Inc (DNTH) estimates and forecasts
Statistics highlight that Dianthus Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -6.74% of value to its shares in past 6 months, showing an annual growth rate of 69.11% while that of industry is 17.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 91.28% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 859.7k for the same. And 7 analysts are in estimates of company making revenue of 796k in the next quarter. Company posted 457k and 874k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.95% during past 5 years.
Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders
Insiders are in possession of 8.76% of company’s total shares while institution are holding 111.72 percent of that, with stock having share float percentage of 122.45%. Investors also watch the number of corporate investors in a company very closely, which is 111.72% institutions for Dianthus Therapeutics Inc that are currently holding shares of the company.
On the other hand, Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 947.18 shares of worth $22.54 million or 3.20% of the total outstanding shares. The later fund manager was in possession of 789.09 shares on Sep 30, 2024 , making its stake of worth around $18.78 million in the company or a holder of 2.67% of company’s stock.
